Law Practice
Jul. 6, 2009
Biotech Firms Merge to 'Survive'
In a trend that is heating up due to turbulent market conditions, San-Francisco-based Cell Genesys announced a $38 million merger with BioSante Pharmaceuticals Inc., of Lincolnshire, Ill.
By Pat Broderick
Daily Journal Staff Writer In a trend that is heating up because of turbulent market conditions, Cell Genesys, a San Francisco-based biotech company, has announced a $38 million merger with BioSante Pharmaceuticals Inc., headquartered in Lincolnshire, Ill. The all-stock deal, approved unanimously by both boards, is expected to be completed later this year pending approval by stockholders, according to Sam Zucker, a partner in the ...
Daily Journal Staff Writer In a trend that is heating up because of turbulent market conditions, Cell Genesys, a San Francisco-based biotech company, has announced a $38 million merger with BioSante Pharmaceuticals Inc., headquartered in Lincolnshire, Ill. The all-stock deal, approved unanimously by both boards, is expected to be completed later this year pending approval by stockholders, according to Sam Zucker, a partner in the ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In